Evidence map›Paper›PMID 39973942›Full record

ReviewThe Lancet regional health. Europe2025

2024 update of the AGIHO guideline on diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients with solid tumours and hematological malignancies.

Michael Sandherr, Jannik Stemler, Enrico Schalk, Tessa Hattenhauer, Marcus Hentrich, Bernd Hertenstein, Christian Hohmann, Sibylle C Mellinghoff, Rebekka Mispelbaum, Christina Rieger and 20 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Lancet regional health. Europe, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Article
  5. ESBL-ProducingPathogens (Basel, Switzerland) · 2026
    Article
  6. Antifungal Management in Patients with Hematological Malignancies: From Primary Prophylaxis to Empirical and Diagnosis-Driven TreatmentTurkish journal of haematology : official journal of Turkish Society of Haematology · 2026
    Review
  7. Review
  8. Observational
  9. Article
  10. Review
  11. Article
  12. Article
  13. Effectiveness and safety of pegylated filgrastim (Pelgraz®) for the prevention of febrile neutropenia during cancer chemotherapy in all-day practice in Germany.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Observational
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Michael SandherrSpecialist Clinic for Hematology and Oncology, Medical Care Center Penzberg, Germany.
Jannik StemlerUniversity of Cologne, Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany.
Enrico SchalkDepartment of Hematology, Oncology and Cell Therapy, Medical Faculty, Otto von Guericke University Magdeburg, Magdeburg, Germany.
Tessa HattenhauerDepartment of Oncology, Hematology, Rheumatology and Immune-Oncology, University Hospital Bonn, Bonn, Germany.
Marcus HentrichDepartment of Hematology and Oncology, Red Cross Hospital Munich, Ludwig Maximilian University Munich, Munich, Germany.
Bernd HertensteinDepartment of Medicine, Clinic I - Hematology, Oncology, Infectiology, Department of Intensive Care and Emergency Medicine, Klinikum Bremen-Mitte, Bremen, Germany.
Christian HohmannDepartment of Medicine, Clinic I - Hematology, Oncology, Infectiology, Department of Intensive Care and Emergency Medicine, Klinikum Bremen-Mitte, Bremen, Germany.
Sibylle C MellinghoffUniversity of Cologne, Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany.
Rebekka MispelbaumDepartment of Oncology, Hematology, Rheumatology and Immune-Oncology, University Hospital Bonn, Bonn, Germany.
Christina RiegerDepartment of Hematology and Oncology Germering, Germering, Germany.
Martin Schmidt-HieberClinic for Oncology, Hematology, Pneumology, Nephrology and Diabetology, Carl-Thiem Clinic, Cottbus, Germany.
Rosanne SpruteUniversity of Cologne, Faculty of Medicine, and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) and Excellence Center for Medical Mycology (ECMM), Cologne, Germany.
Guenter WeissDepartment of Internal Medicine II, Infectious Diseases, Immunology, Rheumatology, Pneumology, Medical University of Innsbruck, Innsbruck, Austria.
Oliver A CornelyUniversity of Cologne, Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany.
Larissa HenzeDepartment of Medicine, Clinic III - Hematology, Oncology, Palliative Medicine, Rostock University Medical Center, Rostock, Germany.
Cornelia Lass-FloerlInstitut of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria.
Gernot BeutelDepartment of Internal Medicine, Hematology, Oncology and Stem Cell Transplantation, Medical University of Hannover, Hannover, Germany.
Annika Y ClassenUniversity of Cologne, Faculty of Medicine, and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) and Excellence Center for Medical Mycology (ECMM), Cologne, Germany.
Noemi F FreiseDepartment of Gastroenterology, Hepatology and Infectious Diseases, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University, Düsseldorf, Germany.
Meinolf KarthausDepartment Hematology, Oncology and Palliative Care, Klinikum Neuperlach and Harlaching, Munich, Germany.
Philipp KoehlerUniversity of Cologne, Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany.
Robert KrauseDivision of Infectious Diseases, Department of Internal Medicine, Medical University of Graz, Austria.
Julia NeuhannUniversity of Cologne, Faculty of Medicine, and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) and Excellence Center for Medical Mycology (ECMM), Cologne, Germany.
Hans Martin OrthDepartment of Gastroenterology, Hepatology and Infectious Diseases, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University, Düsseldorf, Germany.
Olaf PenackCharité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hematology, Oncology and Tumorimmunology, Berlin, Germany.
Markus SchaichDepartment of Hematology, Oncology and Palliative Care, Rems-Murr-Klinikum Winnenden, Germany.
Karsten SpiekermannDepartment of Medicine III, LMU University Hospital, LMU Munich, Germany.
Sebastian VoigtInstitute for Virology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Florian WeissingerEvangelic Hospital Bethel, Bielefeld, Germany.
Elena BuschInternal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Febrile Neutropenia is an emergency in the treatment of cancer patients. It requires prompt and evidence-based clinical and antimicrobial management. The implementation of standard operating procedures (SOP) across hospitals and outpatient cancer departments can improve the outcome of FN patients by reducing FN-related morbidity and mortality and by the continuation of cancer treatment. This guideline describes an evidence-based approach to risk stratification, epidemiology, diagnosis, and treatment. It is provided by the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO) and is an update of the 2017 version. Emerging aspects in epidemiology, diagnostic procedures, risk stratification, first-line antimicrobial treatment, empiric antifungal treatment and the duration of antimicrobial treatment are discussed and rated on evidence-based strength of recommendation and quality of evidence as described by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). By this, the aim of this guideline is to provide evidence-based recommendations on the management of febrile neutropenia in cancer patients for the practicing clinician.

Indexed as

AGIHOAlgorithmAntimicrobial treatmentCancerEvidence-based guidelineFebrile NeutropeniaLeukemia

Identifiers

PMID39973942
PMCPMC11836497

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.